PLATO: Brilinta shows benefit over clopidogrel
This article was originally published in Scrip
Executive Summary
The newly presented full data from AstraZeneca's PLATO study of Brilinta (ticagrelor) show that the novel oral antiplatelet therapy reduced cardiovascular events in patients with acute coronary syndromes by 11.7% compared with 9.8% for clopidogrel (Sanofi-Aventis/Bristol-Myers Squibb's Plavix/Iscover), giving a 16% relative risk reduction with the newer product.